Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia
Introduction Genomic testing is a relatively new, disruptive and complex health technology with multiple clinical applications in rare diseases, cancer and infection control. Genomic testing is increasingly being implemented into clinical practice, following regulatory approval, funding and adoption...
Main Authors: | Kim Dalziel, Zornitza Stark, Ilias Goranitis, Dylan A Mordaunt, Francisco Santos Gonzalez |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/11/e069441.full |
Similar Items
-
Determining the utility of diagnostic genomics: a conceptual framework
by: Andrew Mallett, et al.
Published: (2023-08-01) -
The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom
by: Schwarze, K, et al.
Published: (2019) -
QALYs and rare diseases: exploring the responsiveness of SF-6D, EQ-5D-5L and AQoL-8D following genomic testing for childhood and adult-onset rare genetic conditions in Australia
by: Tianxin Pan, et al.
Published: (2023-12-01) -
Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi
by: Matthew S. Painschab, et al.
Published: (2019-07-01) -
Accurate costs of blood transfusion: a microcosting of administering blood products in the United Kingdom National Health Service
by: Stokes, E, et al.
Published: (2018)